skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Fondaparinux and acute coronary syndromes: update on the OASIS 5–6 studies

Review

(3847) Views  (1129) Full article downloads

Authors: François Schiele

Published Date March 2010 Volume 2010:6 Pages 179 - 187
DOI: http://dx.doi.org/10.2147/VHRM.S6099

François Schiele

Department of Cardiology, University Hospital Jean-Minjoz, Besançon, France

Abstract: Anticoagulant therapy is a major component in the management of acute coronary syndromes (ACS). Four anticoagulant agents are currently commercially available for ACS, namely unfractionated heparin (UFH), enoxaparin, bivalirudin and fondaparinux. We describe the advantages of fondaparinux and the reasons that have hampered its uptake into routine management of ACS. Fondaparinux was shown to be efficacious in the prevention of deep vein thrombosis vs low-molecular-weight heparins, while in the setting of venous thrombo-embolic disease, it was shown to be noninferior to enoxaparin and UFH. Two pivotal studies have demonstrated the efficacy of fondaparinux as an anticoagulant in the setting of ACS, namely OASIS-5 in non-ST elevation ACS, and OASIS-6 in ST elevation myocardial infarction (MI). In OASIS-5, fondaparinux was shown to be noninferior to enoxaparin in terms of death, MI or refractory ischemia at 9 days. Furthermore, a 50% reduction in bleeding complications was obtained with fondaparinux vs enoxaparin, leading to a risk reduction for death. In OASIS-6, fondaparinux was shown to be superior to the comparator (UFH or placebo). European and North American guidelines give fondaparinux a Grade 1A and 1B recommendation respectively, but uptake of fondaparinux in routine practice has been slow. We explore reasons for this, such as prevailing doubts about the efficacy of fondaparinux in the setting of angioplasty, the problem of catheter thrombosis, and the lack of antidote in case of bleeding complications. With the exception of primary angioplasty, fondaparinux is as effective as enoxaparin or UFH, but is also associated with a considerable reduction in bleeding complications, and thus, an undeniable net clinical benefit.

Keywords: fondaparinux, OASIS, acute coronary syndromes








Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Modern role for clopidogrel in management of atrial fibrillation and stroke reduction
Aspirin and clopidogrel resistance: methodological challenges and opportunities
Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention
New standards in hypertension and cardiovascular risk management: focus on telmisartan
Atorvastatin in stroke: a review of SPARCL and subgroup analysis
Recent advances in the management of chronic stable angina I: Approach to the patient, diagnosis, pathophysiology, risk stratification, and gender disparities
Antiplatelet combinations for prevention of atherothrombotic events
Dabigatran for prophylaxis of thromboembolic events in patients with atrial fibrillation
Outcome of the HORIZONS-AMI trial: bivalirudin enhances long-term survival in patients with ST-elevation myocardial infarction undergoing angioplasty
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University